India is grappling with a significant obesity crisis, with an estimated 250 million adults experiencing generalized obesity and nearly 350 million suffering from abdominal obesity. Yet, months after the introduction of generic semaglutide, a breakthrough weight-loss medication, pharmaceutical trade channels are seeing an unexpected build-up of inventory. This disconnect between high disease prevalence and low drug adoption is raising questions about the anticipated boom in India's weight-loss drug market.
Generic Semaglutide Faces Market Hurdles
Following patent expiries, a wave of domestic drugmakers launched generic versions of semaglutide, hoping lower price points would dramatically expand patient access. However, data from Pharmarack indicates that several recently launched semaglutide brands held over 50 days of inventory in May. Dr. Reddy's Mashlo, Glenmark's Glipiq, and Mankind's Semaglu were among those with significant stock excess, suggesting a slower-than-expected uptake.
Beyond Prevalence: Clinical Eligibility and Patient Perception
While the theoretical patient pool for weight management drugs is vast, experts caution that only a fraction truly qualifies for GLP-1 based treatments after rigorous clinical evaluations. Dr. Anoop Misra, Chairman of Fortis C-DOC Hospital for Diabetes and Allied Sciences, notes that while many with a BMI above 23 kg/m² are eligible for intervention, drug therapy is typically reserved for higher BMI levels or those with associated metabolic diseases. He estimates that only 30-40% of eligible individuals might require pharmacological treatment, and 10-20% of those may still opt out due to cost or personal preference.
A significant barrier lies in the perception of obesity itself. Unlike chronic conditions such as diabetes or hypertension, obesity is often viewed as a lifestyle failure rather than a medical disease. Dr. Nandita Palshetkar, a leading gynaecologist, emphasizes that many patients feel guilty about considering medication, believing they should manage weight through diet and exercise alone. This psychological hurdle often leads patients to exhaust other options before seeking prescription therapy.
Cost and Coverage: Major Obstacles
Despite fierce generic competition driving down costs, a monthly semaglutide regimen still amounts to several thousand rupees. For a treatment requiring long-term compliance, the financial burden quickly escalates. Rajesh Pherwani, Founder of Valcreate Investment Managers LLP, highlights that obesity therapies are generally not covered by insurance in India, leaving patients to pay entirely out-of-pocket. This absence of reimbursement is a critical barrier, especially since discontinuing GLP-1s often results in weight rebound, making long-term adherence crucial but expensive.
Side Effects and Physician Selectivity
Awareness of potential side effects also dampens patient enthusiasm. Gastrointestinal issues like nausea and vomiting are common during the initial phase, leading to early discontinuations. Patients are also increasingly concerned about long-term implications such as muscle mass loss and nutritional deficiencies, as noted by Sheetal Sapale, Vice President, Commercial at Pharmarack.
Furthermore, physicians are adopting a highly selective approach, reserving these therapies strictly for individuals meeting rigorous clinical criteria, rather than for cosmetic weight loss. This controlled prescribing, while medically sound, naturally limits rapid market expansion.
Decoding the Inventory Pile-Up
Industry representatives, however, suggest that the current inventory pile-up might not solely reflect low consumer demand. According to the All India Organisation of Chemists & Druggists (AIOCD), the simultaneous launch of generic semaglutide by 31 companies led to massive pipeline stocking by distributors and stockists to ensure nationwide availability. J.S. Shinde, President of AIOCD, explains that the market is now stabilizing after an initial strong stocking phase, transitioning towards a more balanced growth pattern. Analysts project it will take several more months for the supply chain to level out and accurately reflect true underlying consumer demand.